By Tony Fong

NEW YORK (GenomeWeb News) – A slowly improving economy and increasing interest in the potential payoff from molecular diagnostics bodes well for mergers and acquisitions, particularly in the MDx space, according to some experts.

Last year's economic recession resulted in one of the weakest M&A environments in recent memory, but the first half of 2010 has seen a gradual recovery that some say will continue through the balance of the year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.